Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Visit

100 day 6 months 1 year 2 years > 2 years,

Specify:

Disease Assessment at the Time of Best Response to HCT or Cellular Therapy Questions: 1 - 40

What was the best response to HCT or cellular therapy since the date of the last report? (Include response to any therapy given for post-HCT / post-infusion maintenance or
consolidation, but exclude any therapy given for relapsed, persistent, or progressive disease)

1

Continued complete remission (CCR) - For patients transplant in CR

Complete
remission (CR)

- All of the following response criteria without progression for at least four weeks: < 5% blasts in the bone marrow, no blasts with Auer rods, no
extramedullary disease (e.g., central nervous system or soft tissue involvement)

Not in complete remission

Was the date of best response previously reported?

yes no

2

Date assessed:3 __ __ __ __ - __ __- __ __

Were tests for molecular markers performed? (e.g. PCR, NGS) (at time of best response)

yes no Unknown

4

CEBPA

Positive Negative Not Done

5

Specify CEBPA mutation6

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

7

FLT3 – ITD mutation

Positive Negative Not Done

8

IDH1

Positive Negative Not Done

9

IDH2

Positive Negative Not Done

10

KIT

Positive Negative Not Done

11

NPM1

Positive Negative Not Done

12

Multiple Molecular Markers (1) Questions: 13 - 14

Other molecular marker

Positive Negative Not Done

13

Specify other molecular marker:14

Was the disease status assessed via flow cytometry?

yes no

15

Blood

yes no

16

Date sample collected:17 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

18

Specify percent disease detected:19 %

Bone marrow

yes no

20

Date sample collected:21 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

22

Specify percent disease detected:23 %

Were cytogenetics tested (karyotyping or FISH)? (at time of best response)

yes no Unknown

24

Were cytogenetics tested via FISH?

Yes No

25

Results of tests26

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities27

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

28

Specify other abnormality:29

Were cytogenetics tested via karyotyping?

Yes No

30

Results of tests31

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities32

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

33

Specify other abnormality:34

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

35

Was disease status assessed by other assessment?

Yes No

36

Date assessed:37 __ __ __ __ - __ __- __ __

Specify other assessment:38

Was disease detected?

yes no

39

Was the status considered a disease relapse?

yes no

40

Post-HCT / Post-InfusionTherapy Questions: 41 - 50

Was therapy given since the date of the last report for reasons other than relapse or persistent disease? (Include any maintenance and consolidation therapy.)

yes no

41

Central nervous system irradiation

yes no

42

Systemic therapy

yes no

43

Date therapy was first started44

Known

Unknown

Previously reported (e.g. started in/continuing from a prior reporting period)

Date first started:45 __ __ __ __ - __ __- __ __

Specify systemic therapy given (for reasons other than relapse or persistent disease (check all that apply)

Azacytidine

All-trans retinoic acid

Decitabine

Intrathecal therapy

Midostaurin

Sorafenib

Thioguanine

Other systemic therapy

46

(Vidaza)

(Tretinoin)

(Dacogen)

(6-TG)

Specify other systemic therapy:47

Cellular therapy (e.g. donor cellular infusions (DCI),CAR T-cells)48

yes -Also complete Pre-CTED form 4000

no

Other therapy

yes no

49

Specify other therapy:50

Disease Detection Since the Date of Last Report Questions: 51 - 103

Were tests for molecular markers performed? (and positive for disease) (e.g. PCR, NGS)

yes no Unknown

51

Date sample collected:52 __ __ __ __ - __ __- __ __

CEBPA

Positive Negative Not Done

53

Specify CEBPA mutation54

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

55

FLT3 – ITD mutation

Positive Negative Not Done

56

IDH1

Positive Negative Not Done

57

IDH2

Positive Negative Not Done

58

KIT

Positive Negative Not Done

59

NPM1

Positive Negative Not Done

60

Multiple Molecular Markers (1) Questions: 61 - 62

Other molecular marker

Positive Negative Not Done

61

Specify other molecular marker:62

Was disease detected via flow cytometry?

Yes No

63

Blood

yes no

64

Date sample collected:65 __ __ __ __ - __ __- __ __

Specify percent disease detected:66 %

Bone marrow

yes no

67

Date sample collected:68 __ __ __ __ - __ __- __ __

Specify percent disease detected:69 %

Was disease detected via cytogenetics testing? (karyotyping or FISH)

Yes No Unknown

70

Were cytogenetic abnormalities identified via FISH?

Yes No

71

Date sample collected:72 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

73

Specify other abnormality:74

Were cytogenetic abnormalities identified via karyotyping?

Yes No

75

Date sample collected:76 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

77

Specify other abnormality:78

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

79

Was disease detected by clinical / hematologic assessment?

Yes No

80

Date assessed:81 __ __ __ __ - __ __- __ __

Central nervous system

Yes No

82

Skin

yes no

83

Soft tissue

yes no

84

Other site

yes no

85

Specify other site:86

Was disease detected by other assessment?

Yes No

87

Date assessed:88 __ __ __ __ - __ __- __ __

Specify other assessment:89

Was intervention given for relapsed, persistent or progressive disease, or decreased/loss of chimerism since the date of last report?

Yes No

90

Intervention Given (1) Questions: 91 - 103

Specify reason for which intervention was given91

Minimal residual disease

Persistent disease

Relapsed disase

Central nervous system irradiation

yes no

92

Intrathecal therapy

yes no

93

Systemic therapy

yes no

94

Date therapy was first started95

Known

Unknown

Previously reported (e.g. started in a prior reporting period/continued from prior reporting period)

Date first started:96 __ __ __ __ - __ __- __ __

Specify systemic therapy given (check all that apply)

Azacytidine

All-trans retinoic acid

Arsenic

Cladribine

Clofarabine

Cytarabine (Ara ­ C) ≤ 10 g/m2/cycle

cytarabine (Ara - C) > 10 g/m2/cycle

Daunorubicin

Decitabine

Etoposide

Fludarabine

Gemtuzumab

Idarubicin

Midostaurin

Mitoxantrone

Sorafenib

Thioguanine

Other systemic therapy

97

(Vidaza)

(Tretinoin)

(2-CDA, Leustatin)

(Cerubidine)

(Dacogen) 

(VP-16, VePesid)

(Fludara)

(Mylotarg)

(Idamycin)

(Novantrone)

(6-TG)

Specify other systemic therapy:98

Cellular therapy (e.g. donor cellular infusions (DCI), CAR T-cells)99

yes -Also complete Pre-CTED form 4000

no

Subsequent HCT100

yes -Also complete Pre-TED form 2400

no

Accelerated withdrawal of immunosuppression in response to disease assessment

Yes No

101

Other therapy

yes no

102

Specify other therapy:103

Disease Status at the Time of Evaluation for this Reporting Period Questions: 104 - 145

Does the disease status reflect the disease detected in this reporting period section without subsequent therapy? (as captured in questions 51-89)

Yes No Not Applicable

104

Were tests for molecular markers performed? (e.g. PCR, NGS)

yes no Unknown

105

CEBPA

Positive Negative Not Done

106

Specify CEBPA mutation107

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

108

FLT3 – ITD mutation

Positive Negative Not Done

109

IDH1

Positive Negative Not Done

110

IDH2

Positive Negative Not Done

111

KIT

Positive Negative Not Done

112

NPM1

Positive Negative Not Done

113

Current Molecular Marker (1) Questions: 114 - 115

Other molecular marker

Positive Negative Not Done

114

Specify other molecular marker:115

Was the disease status assessed via flow cytometry?

yes no

116

Blood

yes no

117

Date sample collected:118 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

119

Specify percent disease detected:120 %

Bone marrow

yes no

121

Date sample collected:122 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

123

Specify percent disease detected:124 %

Were cytogenetics tested? (karyotyping or FISH)

yes no Unknown

125

Were cytogenetics tested via FISH?

yes no Unknown

126

Results of tests127

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities128

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

129

Specify other abnormality:130

Were cytogenetics tested via karyotyping?

Yes No Unknown

131

Results of tests132

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities133

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

134

Specify other abnormality:135

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

136

Was the disease status assessed by clinical / hematologic assessment?

yes no

137

Date assessed:138 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

139

Was disease status assessed by other assessment?

Yes No

140

Date assessed:141 __ __ __ __ - __ __- __ __

Specify other assessment:142

Was disease detected?

yes no

143

What is the current disease status?144

Complete remission (CR)

Not in complete remission

Date assessed:145 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Specify molecular markers identified at time of best response:

Specify tissue and results at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify therapy given:

Specify systemic therapy given for reasons other than relapse or persistent disease:

Specify molecular markers identified since the date of last report:

Specify tissue and results:

Specify site(s) of disease:

Specify the method(s) used to assess the disease status at the time of evaluation for this reporting period:

Specify molecular markers identified:

Specify tissue and results at the time of evaluation for this reporting period:

Specify cytogenetic abnormalities identified:

Specify cytogenetic abnormalities identified:

Center: CRID: 

Form 2110 R4.0: Acute Myelogenous Leukemia (AML) Post-Infusion Data

CIBMTR Form 2110 revision 4.0 last updated Wednesday, August 16, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 1 / 11



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Visit

100 day 6 months 1 year 2 years > 2 years,

Specify:

Disease Assessment at the Time of Best Response to HCT or Cellular Therapy Questions: 1 - 40

What was the best response to HCT or cellular therapy since the date of the last report? (Include response to any therapy given for post-HCT / post-infusion maintenance or
consolidation, but exclude any therapy given for relapsed, persistent, or progressive disease)

1

Continued complete remission (CCR) - For patients transplant in CR

Complete
remission (CR)

- All of the following response criteria without progression for at least four weeks: < 5% blasts in the bone marrow, no blasts with Auer rods, no
extramedullary disease (e.g., central nervous system or soft tissue involvement)

Not in complete remission

Was the date of best response previously reported?

yes no

2

Date assessed:3 __ __ __ __ - __ __- __ __

Were tests for molecular markers performed? (e.g. PCR, NGS) (at time of best response)

yes no Unknown

4

CEBPA

Positive Negative Not Done

5

Specify CEBPA mutation6

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

7

FLT3 – ITD mutation

Positive Negative Not Done

8

IDH1

Positive Negative Not Done

9

IDH2

Positive Negative Not Done

10

KIT

Positive Negative Not Done

11

NPM1

Positive Negative Not Done

12

Multiple Molecular Markers (1) Questions: 13 - 14

Other molecular marker

Positive Negative Not Done

13

Specify other molecular marker:14

Was the disease status assessed via flow cytometry?

yes no

15

Blood

yes no

16

Date sample collected:17 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

18

Specify percent disease detected:19 %

Bone marrow

yes no

20

Date sample collected:21 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

22

Specify percent disease detected:23 %

Were cytogenetics tested (karyotyping or FISH)? (at time of best response)

yes no Unknown

24

Were cytogenetics tested via FISH?

Yes No

25

Results of tests26

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities27

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

28

Specify other abnormality:29

Were cytogenetics tested via karyotyping?

Yes No

30

Results of tests31

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities32

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

33

Specify other abnormality:34

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

35

Was disease status assessed by other assessment?

Yes No

36

Date assessed:37 __ __ __ __ - __ __- __ __

Specify other assessment:38

Was disease detected?

yes no

39

Was the status considered a disease relapse?

yes no

40

Post-HCT / Post-InfusionTherapy Questions: 41 - 50

Was therapy given since the date of the last report for reasons other than relapse or persistent disease? (Include any maintenance and consolidation therapy.)

yes no

41

Central nervous system irradiation

yes no

42

Systemic therapy

yes no

43

Date therapy was first started44

Known

Unknown

Previously reported (e.g. started in/continuing from a prior reporting period)

Date first started:45 __ __ __ __ - __ __- __ __

Specify systemic therapy given (for reasons other than relapse or persistent disease (check all that apply)

Azacytidine

All-trans retinoic acid

Decitabine

Intrathecal therapy

Midostaurin

Sorafenib

Thioguanine

Other systemic therapy

46

(Vidaza)

(Tretinoin)

(Dacogen)

(6-TG)

Specify other systemic therapy:47

Cellular therapy (e.g. donor cellular infusions (DCI),CAR T-cells)48

yes -Also complete Pre-CTED form 4000

no

Other therapy

yes no

49

Specify other therapy:50

Disease Detection Since the Date of Last Report Questions: 51 - 103

Were tests for molecular markers performed? (and positive for disease) (e.g. PCR, NGS)

yes no Unknown

51

Date sample collected:52 __ __ __ __ - __ __- __ __

CEBPA

Positive Negative Not Done

53

Specify CEBPA mutation54

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

55

FLT3 – ITD mutation

Positive Negative Not Done

56

IDH1

Positive Negative Not Done

57

IDH2

Positive Negative Not Done

58

KIT

Positive Negative Not Done

59

NPM1

Positive Negative Not Done

60

Multiple Molecular Markers (1) Questions: 61 - 62

Other molecular marker

Positive Negative Not Done

61

Specify other molecular marker:62

Was disease detected via flow cytometry?

Yes No

63

Blood

yes no

64

Date sample collected:65 __ __ __ __ - __ __- __ __

Specify percent disease detected:66 %

Bone marrow

yes no

67

Date sample collected:68 __ __ __ __ - __ __- __ __

Specify percent disease detected:69 %

Was disease detected via cytogenetics testing? (karyotyping or FISH)

Yes No Unknown

70

Were cytogenetic abnormalities identified via FISH?

Yes No

71

Date sample collected:72 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

73

Specify other abnormality:74

Were cytogenetic abnormalities identified via karyotyping?

Yes No

75

Date sample collected:76 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

77

Specify other abnormality:78

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

79

Was disease detected by clinical / hematologic assessment?

Yes No

80

Date assessed:81 __ __ __ __ - __ __- __ __

Central nervous system

Yes No

82

Skin

yes no

83

Soft tissue

yes no

84

Other site

yes no

85

Specify other site:86

Was disease detected by other assessment?

Yes No

87

Date assessed:88 __ __ __ __ - __ __- __ __

Specify other assessment:89

Was intervention given for relapsed, persistent or progressive disease, or decreased/loss of chimerism since the date of last report?

Yes No

90

Intervention Given (1) Questions: 91 - 103

Specify reason for which intervention was given91

Minimal residual disease

Persistent disease

Relapsed disase

Central nervous system irradiation

yes no

92

Intrathecal therapy

yes no

93

Systemic therapy

yes no

94

Date therapy was first started95

Known

Unknown

Previously reported (e.g. started in a prior reporting period/continued from prior reporting period)

Date first started:96 __ __ __ __ - __ __- __ __

Specify systemic therapy given (check all that apply)

Azacytidine

All-trans retinoic acid

Arsenic

Cladribine

Clofarabine

Cytarabine (Ara ­ C) ≤ 10 g/m2/cycle

cytarabine (Ara - C) > 10 g/m2/cycle

Daunorubicin

Decitabine

Etoposide

Fludarabine

Gemtuzumab

Idarubicin

Midostaurin

Mitoxantrone

Sorafenib

Thioguanine

Other systemic therapy

97

(Vidaza)

(Tretinoin)

(2-CDA, Leustatin)

(Cerubidine)

(Dacogen) 

(VP-16, VePesid)

(Fludara)

(Mylotarg)

(Idamycin)

(Novantrone)

(6-TG)

Specify other systemic therapy:98

Cellular therapy (e.g. donor cellular infusions (DCI), CAR T-cells)99

yes -Also complete Pre-CTED form 4000

no

Subsequent HCT100

yes -Also complete Pre-TED form 2400

no

Accelerated withdrawal of immunosuppression in response to disease assessment

Yes No

101

Other therapy

yes no

102

Specify other therapy:103

Disease Status at the Time of Evaluation for this Reporting Period Questions: 104 - 145

Does the disease status reflect the disease detected in this reporting period section without subsequent therapy? (as captured in questions 51-89)

Yes No Not Applicable

104

Were tests for molecular markers performed? (e.g. PCR, NGS)

yes no Unknown

105

CEBPA

Positive Negative Not Done

106

Specify CEBPA mutation107

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

108

FLT3 – ITD mutation

Positive Negative Not Done

109

IDH1

Positive Negative Not Done

110

IDH2

Positive Negative Not Done

111

KIT

Positive Negative Not Done

112

NPM1

Positive Negative Not Done

113

Current Molecular Marker (1) Questions: 114 - 115

Other molecular marker

Positive Negative Not Done

114

Specify other molecular marker:115

Was the disease status assessed via flow cytometry?

yes no

116

Blood

yes no

117

Date sample collected:118 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

119

Specify percent disease detected:120 %

Bone marrow

yes no

121

Date sample collected:122 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

123

Specify percent disease detected:124 %

Were cytogenetics tested? (karyotyping or FISH)

yes no Unknown

125

Were cytogenetics tested via FISH?

yes no Unknown

126

Results of tests127

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities128

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

129

Specify other abnormality:130

Were cytogenetics tested via karyotyping?

Yes No Unknown

131

Results of tests132

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities133

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

134

Specify other abnormality:135

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

136

Was the disease status assessed by clinical / hematologic assessment?

yes no

137

Date assessed:138 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

139

Was disease status assessed by other assessment?

Yes No

140

Date assessed:141 __ __ __ __ - __ __- __ __

Specify other assessment:142

Was disease detected?

yes no

143

What is the current disease status?144

Complete remission (CR)

Not in complete remission

Date assessed:145 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Specify molecular markers identified at time of best response:

Specify tissue and results at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify therapy given:

Specify systemic therapy given for reasons other than relapse or persistent disease:

Specify molecular markers identified since the date of last report:

Specify tissue and results:

Specify site(s) of disease:

Specify the method(s) used to assess the disease status at the time of evaluation for this reporting period:

Specify molecular markers identified:

Specify tissue and results at the time of evaluation for this reporting period:

Specify cytogenetic abnormalities identified:

Specify cytogenetic abnormalities identified:

Center: CRID: 

Form 2110 R4.0: Acute Myelogenous Leukemia (AML) Post-Infusion Data

CIBMTR Form 2110 revision 4.0 last updated Wednesday, August 16, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 2 / 11



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Visit

100 day 6 months 1 year 2 years > 2 years,

Specify:

Disease Assessment at the Time of Best Response to HCT or Cellular Therapy Questions: 1 - 40

What was the best response to HCT or cellular therapy since the date of the last report? (Include response to any therapy given for post-HCT / post-infusion maintenance or
consolidation, but exclude any therapy given for relapsed, persistent, or progressive disease)

1

Continued complete remission (CCR) - For patients transplant in CR

Complete
remission (CR)

- All of the following response criteria without progression for at least four weeks: < 5% blasts in the bone marrow, no blasts with Auer rods, no
extramedullary disease (e.g., central nervous system or soft tissue involvement)

Not in complete remission

Was the date of best response previously reported?

yes no

2

Date assessed:3 __ __ __ __ - __ __- __ __

Were tests for molecular markers performed? (e.g. PCR, NGS) (at time of best response)

yes no Unknown

4

CEBPA

Positive Negative Not Done

5

Specify CEBPA mutation6

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

7

FLT3 – ITD mutation

Positive Negative Not Done

8

IDH1

Positive Negative Not Done

9

IDH2

Positive Negative Not Done

10

KIT

Positive Negative Not Done

11

NPM1

Positive Negative Not Done

12

Multiple Molecular Markers (1) Questions: 13 - 14

Other molecular marker

Positive Negative Not Done

13

Specify other molecular marker:14

Was the disease status assessed via flow cytometry?

yes no

15

Blood

yes no

16

Date sample collected:17 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

18

Specify percent disease detected:19 %

Bone marrow

yes no

20

Date sample collected:21 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

22

Specify percent disease detected:23 %

Were cytogenetics tested (karyotyping or FISH)? (at time of best response)

yes no Unknown

24

Were cytogenetics tested via FISH?

Yes No

25

Results of tests26

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities27

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

28

Specify other abnormality:29

Were cytogenetics tested via karyotyping?

Yes No

30

Results of tests31

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities32

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

33

Specify other abnormality:34

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

35

Was disease status assessed by other assessment?

Yes No

36

Date assessed:37 __ __ __ __ - __ __- __ __

Specify other assessment:38

Was disease detected?

yes no

39

Was the status considered a disease relapse?

yes no

40

Post-HCT / Post-InfusionTherapy Questions: 41 - 50

Was therapy given since the date of the last report for reasons other than relapse or persistent disease? (Include any maintenance and consolidation therapy.)

yes no

41

Central nervous system irradiation

yes no

42

Systemic therapy

yes no

43

Date therapy was first started44

Known

Unknown

Previously reported (e.g. started in/continuing from a prior reporting period)

Date first started:45 __ __ __ __ - __ __- __ __

Specify systemic therapy given (for reasons other than relapse or persistent disease (check all that apply)

Azacytidine

All-trans retinoic acid

Decitabine

Intrathecal therapy

Midostaurin

Sorafenib

Thioguanine

Other systemic therapy

46

(Vidaza)

(Tretinoin)

(Dacogen)

(6-TG)

Specify other systemic therapy:47

Cellular therapy (e.g. donor cellular infusions (DCI),CAR T-cells)48

yes -Also complete Pre-CTED form 4000

no

Other therapy

yes no

49

Specify other therapy:50

Disease Detection Since the Date of Last Report Questions: 51 - 103

Were tests for molecular markers performed? (and positive for disease) (e.g. PCR, NGS)

yes no Unknown

51

Date sample collected:52 __ __ __ __ - __ __- __ __

CEBPA

Positive Negative Not Done

53

Specify CEBPA mutation54

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

55

FLT3 – ITD mutation

Positive Negative Not Done

56

IDH1

Positive Negative Not Done

57

IDH2

Positive Negative Not Done

58

KIT

Positive Negative Not Done

59

NPM1

Positive Negative Not Done

60

Multiple Molecular Markers (1) Questions: 61 - 62

Other molecular marker

Positive Negative Not Done

61

Specify other molecular marker:62

Was disease detected via flow cytometry?

Yes No

63

Blood

yes no

64

Date sample collected:65 __ __ __ __ - __ __- __ __

Specify percent disease detected:66 %

Bone marrow

yes no

67

Date sample collected:68 __ __ __ __ - __ __- __ __

Specify percent disease detected:69 %

Was disease detected via cytogenetics testing? (karyotyping or FISH)

Yes No Unknown

70

Were cytogenetic abnormalities identified via FISH?

Yes No

71

Date sample collected:72 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

73

Specify other abnormality:74

Were cytogenetic abnormalities identified via karyotyping?

Yes No

75

Date sample collected:76 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

77

Specify other abnormality:78

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

79

Was disease detected by clinical / hematologic assessment?

Yes No

80

Date assessed:81 __ __ __ __ - __ __- __ __

Central nervous system

Yes No

82

Skin

yes no

83

Soft tissue

yes no

84

Other site

yes no

85

Specify other site:86

Was disease detected by other assessment?

Yes No

87

Date assessed:88 __ __ __ __ - __ __- __ __

Specify other assessment:89

Was intervention given for relapsed, persistent or progressive disease, or decreased/loss of chimerism since the date of last report?

Yes No

90

Intervention Given (1) Questions: 91 - 103

Specify reason for which intervention was given91

Minimal residual disease

Persistent disease

Relapsed disase

Central nervous system irradiation

yes no

92

Intrathecal therapy

yes no

93

Systemic therapy

yes no

94

Date therapy was first started95

Known

Unknown

Previously reported (e.g. started in a prior reporting period/continued from prior reporting period)

Date first started:96 __ __ __ __ - __ __- __ __

Specify systemic therapy given (check all that apply)

Azacytidine

All-trans retinoic acid

Arsenic

Cladribine

Clofarabine

Cytarabine (Ara ­ C) ≤ 10 g/m2/cycle

cytarabine (Ara - C) > 10 g/m2/cycle

Daunorubicin

Decitabine

Etoposide

Fludarabine

Gemtuzumab

Idarubicin

Midostaurin

Mitoxantrone

Sorafenib

Thioguanine

Other systemic therapy

97

(Vidaza)

(Tretinoin)

(2-CDA, Leustatin)

(Cerubidine)

(Dacogen) 

(VP-16, VePesid)

(Fludara)

(Mylotarg)

(Idamycin)

(Novantrone)

(6-TG)

Specify other systemic therapy:98

Cellular therapy (e.g. donor cellular infusions (DCI), CAR T-cells)99

yes -Also complete Pre-CTED form 4000

no

Subsequent HCT100

yes -Also complete Pre-TED form 2400

no

Accelerated withdrawal of immunosuppression in response to disease assessment

Yes No

101

Other therapy

yes no

102

Specify other therapy:103

Disease Status at the Time of Evaluation for this Reporting Period Questions: 104 - 145

Does the disease status reflect the disease detected in this reporting period section without subsequent therapy? (as captured in questions 51-89)

Yes No Not Applicable

104

Were tests for molecular markers performed? (e.g. PCR, NGS)

yes no Unknown

105

CEBPA

Positive Negative Not Done

106

Specify CEBPA mutation107

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

108

FLT3 – ITD mutation

Positive Negative Not Done

109

IDH1

Positive Negative Not Done

110

IDH2

Positive Negative Not Done

111

KIT

Positive Negative Not Done

112

NPM1

Positive Negative Not Done

113

Current Molecular Marker (1) Questions: 114 - 115

Other molecular marker

Positive Negative Not Done

114

Specify other molecular marker:115

Was the disease status assessed via flow cytometry?

yes no

116

Blood

yes no

117

Date sample collected:118 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

119

Specify percent disease detected:120 %

Bone marrow

yes no

121

Date sample collected:122 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

123

Specify percent disease detected:124 %

Were cytogenetics tested? (karyotyping or FISH)

yes no Unknown

125

Were cytogenetics tested via FISH?

yes no Unknown

126

Results of tests127

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities128

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

129

Specify other abnormality:130

Were cytogenetics tested via karyotyping?

Yes No Unknown

131

Results of tests132

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities133

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

134

Specify other abnormality:135

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

136

Was the disease status assessed by clinical / hematologic assessment?

yes no

137

Date assessed:138 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

139

Was disease status assessed by other assessment?

Yes No

140

Date assessed:141 __ __ __ __ - __ __- __ __

Specify other assessment:142

Was disease detected?

yes no

143

What is the current disease status?144

Complete remission (CR)

Not in complete remission

Date assessed:145 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Specify molecular markers identified at time of best response:

Specify tissue and results at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify therapy given:

Specify systemic therapy given for reasons other than relapse or persistent disease:

Specify molecular markers identified since the date of last report:

Specify tissue and results:

Specify site(s) of disease:

Specify the method(s) used to assess the disease status at the time of evaluation for this reporting period:

Specify molecular markers identified:

Specify tissue and results at the time of evaluation for this reporting period:

Specify cytogenetic abnormalities identified:

Specify cytogenetic abnormalities identified:

Center: CRID: 

Form 2110 R4.0: Acute Myelogenous Leukemia (AML) Post-Infusion Data

CIBMTR Form 2110 revision 4.0 last updated Wednesday, August 16, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 3 / 11



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Visit

100 day 6 months 1 year 2 years > 2 years,

Specify:

Disease Assessment at the Time of Best Response to HCT or Cellular Therapy Questions: 1 - 40

What was the best response to HCT or cellular therapy since the date of the last report? (Include response to any therapy given for post-HCT / post-infusion maintenance or
consolidation, but exclude any therapy given for relapsed, persistent, or progressive disease)

1

Continued complete remission (CCR) - For patients transplant in CR

Complete
remission (CR)

- All of the following response criteria without progression for at least four weeks: < 5% blasts in the bone marrow, no blasts with Auer rods, no
extramedullary disease (e.g., central nervous system or soft tissue involvement)

Not in complete remission

Was the date of best response previously reported?

yes no

2

Date assessed:3 __ __ __ __ - __ __- __ __

Were tests for molecular markers performed? (e.g. PCR, NGS) (at time of best response)

yes no Unknown

4

CEBPA

Positive Negative Not Done

5

Specify CEBPA mutation6

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

7

FLT3 – ITD mutation

Positive Negative Not Done

8

IDH1

Positive Negative Not Done

9

IDH2

Positive Negative Not Done

10

KIT

Positive Negative Not Done

11

NPM1

Positive Negative Not Done

12

Multiple Molecular Markers (1) Questions: 13 - 14

Other molecular marker

Positive Negative Not Done

13

Specify other molecular marker:14

Was the disease status assessed via flow cytometry?

yes no

15

Blood

yes no

16

Date sample collected:17 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

18

Specify percent disease detected:19 %

Bone marrow

yes no

20

Date sample collected:21 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

22

Specify percent disease detected:23 %

Were cytogenetics tested (karyotyping or FISH)? (at time of best response)

yes no Unknown

24

Were cytogenetics tested via FISH?

Yes No

25

Results of tests26

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities27

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

28

Specify other abnormality:29

Were cytogenetics tested via karyotyping?

Yes No

30

Results of tests31

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities32

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

33

Specify other abnormality:34

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

35

Was disease status assessed by other assessment?

Yes No

36

Date assessed:37 __ __ __ __ - __ __- __ __

Specify other assessment:38

Was disease detected?

yes no

39

Was the status considered a disease relapse?

yes no

40

Post-HCT / Post-InfusionTherapy Questions: 41 - 50

Was therapy given since the date of the last report for reasons other than relapse or persistent disease? (Include any maintenance and consolidation therapy.)

yes no

41

Central nervous system irradiation

yes no

42

Systemic therapy

yes no

43

Date therapy was first started44

Known

Unknown

Previously reported (e.g. started in/continuing from a prior reporting period)

Date first started:45 __ __ __ __ - __ __- __ __

Specify systemic therapy given (for reasons other than relapse or persistent disease (check all that apply)

Azacytidine

All-trans retinoic acid

Decitabine

Intrathecal therapy

Midostaurin

Sorafenib

Thioguanine

Other systemic therapy

46

(Vidaza)

(Tretinoin)

(Dacogen)

(6-TG)

Specify other systemic therapy:47

Cellular therapy (e.g. donor cellular infusions (DCI),CAR T-cells)48

yes -Also complete Pre-CTED form 4000

no

Other therapy

yes no

49

Specify other therapy:50

Disease Detection Since the Date of Last Report Questions: 51 - 103

Were tests for molecular markers performed? (and positive for disease) (e.g. PCR, NGS)

yes no Unknown

51

Date sample collected:52 __ __ __ __ - __ __- __ __

CEBPA

Positive Negative Not Done

53

Specify CEBPA mutation54

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

55

FLT3 – ITD mutation

Positive Negative Not Done

56

IDH1

Positive Negative Not Done

57

IDH2

Positive Negative Not Done

58

KIT

Positive Negative Not Done

59

NPM1

Positive Negative Not Done

60

Multiple Molecular Markers (1) Questions: 61 - 62

Other molecular marker

Positive Negative Not Done

61

Specify other molecular marker:62

Was disease detected via flow cytometry?

Yes No

63

Blood

yes no

64

Date sample collected:65 __ __ __ __ - __ __- __ __

Specify percent disease detected:66 %

Bone marrow

yes no

67

Date sample collected:68 __ __ __ __ - __ __- __ __

Specify percent disease detected:69 %

Was disease detected via cytogenetics testing? (karyotyping or FISH)

Yes No Unknown

70

Were cytogenetic abnormalities identified via FISH?

Yes No

71

Date sample collected:72 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

73

Specify other abnormality:74

Were cytogenetic abnormalities identified via karyotyping?

Yes No

75

Date sample collected:76 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

77

Specify other abnormality:78

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

79

Was disease detected by clinical / hematologic assessment?

Yes No

80

Date assessed:81 __ __ __ __ - __ __- __ __

Central nervous system

Yes No

82

Skin

yes no

83

Soft tissue

yes no

84

Other site

yes no

85

Specify other site:86

Was disease detected by other assessment?

Yes No

87

Date assessed:88 __ __ __ __ - __ __- __ __

Specify other assessment:89

Was intervention given for relapsed, persistent or progressive disease, or decreased/loss of chimerism since the date of last report?

Yes No

90

Intervention Given (1) Questions: 91 - 103

Specify reason for which intervention was given91

Minimal residual disease

Persistent disease

Relapsed disase

Central nervous system irradiation

yes no

92

Intrathecal therapy

yes no

93

Systemic therapy

yes no

94

Date therapy was first started95

Known

Unknown

Previously reported (e.g. started in a prior reporting period/continued from prior reporting period)

Date first started:96 __ __ __ __ - __ __- __ __

Specify systemic therapy given (check all that apply)

Azacytidine

All-trans retinoic acid

Arsenic

Cladribine

Clofarabine

Cytarabine (Ara ­ C) ≤ 10 g/m2/cycle

cytarabine (Ara - C) > 10 g/m2/cycle

Daunorubicin

Decitabine

Etoposide

Fludarabine

Gemtuzumab

Idarubicin

Midostaurin

Mitoxantrone

Sorafenib

Thioguanine

Other systemic therapy

97

(Vidaza)

(Tretinoin)

(2-CDA, Leustatin)

(Cerubidine)

(Dacogen) 

(VP-16, VePesid)

(Fludara)

(Mylotarg)

(Idamycin)

(Novantrone)

(6-TG)

Specify other systemic therapy:98

Cellular therapy (e.g. donor cellular infusions (DCI), CAR T-cells)99

yes -Also complete Pre-CTED form 4000

no

Subsequent HCT100

yes -Also complete Pre-TED form 2400

no

Accelerated withdrawal of immunosuppression in response to disease assessment

Yes No

101

Other therapy

yes no

102

Specify other therapy:103

Disease Status at the Time of Evaluation for this Reporting Period Questions: 104 - 145

Does the disease status reflect the disease detected in this reporting period section without subsequent therapy? (as captured in questions 51-89)

Yes No Not Applicable

104

Were tests for molecular markers performed? (e.g. PCR, NGS)

yes no Unknown

105

CEBPA

Positive Negative Not Done

106

Specify CEBPA mutation107

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

108

FLT3 – ITD mutation

Positive Negative Not Done

109

IDH1

Positive Negative Not Done

110

IDH2

Positive Negative Not Done

111

KIT

Positive Negative Not Done

112

NPM1

Positive Negative Not Done

113

Current Molecular Marker (1) Questions: 114 - 115

Other molecular marker

Positive Negative Not Done

114

Specify other molecular marker:115

Was the disease status assessed via flow cytometry?

yes no

116

Blood

yes no

117

Date sample collected:118 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

119

Specify percent disease detected:120 %

Bone marrow

yes no

121

Date sample collected:122 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

123

Specify percent disease detected:124 %

Were cytogenetics tested? (karyotyping or FISH)

yes no Unknown

125

Were cytogenetics tested via FISH?

yes no Unknown

126

Results of tests127

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities128

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

129

Specify other abnormality:130

Were cytogenetics tested via karyotyping?

Yes No Unknown

131

Results of tests132

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities133

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

134

Specify other abnormality:135

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

136

Was the disease status assessed by clinical / hematologic assessment?

yes no

137

Date assessed:138 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

139

Was disease status assessed by other assessment?

Yes No

140

Date assessed:141 __ __ __ __ - __ __- __ __

Specify other assessment:142

Was disease detected?

yes no

143

What is the current disease status?144

Complete remission (CR)

Not in complete remission

Date assessed:145 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Specify molecular markers identified at time of best response:

Specify tissue and results at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify therapy given:

Specify systemic therapy given for reasons other than relapse or persistent disease:

Specify molecular markers identified since the date of last report:

Specify tissue and results:

Specify site(s) of disease:

Specify the method(s) used to assess the disease status at the time of evaluation for this reporting period:

Specify molecular markers identified:

Specify tissue and results at the time of evaluation for this reporting period:

Specify cytogenetic abnormalities identified:

Specify cytogenetic abnormalities identified:

Center: CRID: 

Form 2110 R4.0: Acute Myelogenous Leukemia (AML) Post-Infusion Data

CIBMTR Form 2110 revision 4.0 last updated Wednesday, August 16, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 4 / 11



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Visit

100 day 6 months 1 year 2 years > 2 years,

Specify:

Disease Assessment at the Time of Best Response to HCT or Cellular Therapy Questions: 1 - 40

What was the best response to HCT or cellular therapy since the date of the last report? (Include response to any therapy given for post-HCT / post-infusion maintenance or
consolidation, but exclude any therapy given for relapsed, persistent, or progressive disease)

1

Continued complete remission (CCR) - For patients transplant in CR

Complete
remission (CR)

- All of the following response criteria without progression for at least four weeks: < 5% blasts in the bone marrow, no blasts with Auer rods, no
extramedullary disease (e.g., central nervous system or soft tissue involvement)

Not in complete remission

Was the date of best response previously reported?

yes no

2

Date assessed:3 __ __ __ __ - __ __- __ __

Were tests for molecular markers performed? (e.g. PCR, NGS) (at time of best response)

yes no Unknown

4

CEBPA

Positive Negative Not Done

5

Specify CEBPA mutation6

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

7

FLT3 – ITD mutation

Positive Negative Not Done

8

IDH1

Positive Negative Not Done

9

IDH2

Positive Negative Not Done

10

KIT

Positive Negative Not Done

11

NPM1

Positive Negative Not Done

12

Multiple Molecular Markers (1) Questions: 13 - 14

Other molecular marker

Positive Negative Not Done

13

Specify other molecular marker:14

Was the disease status assessed via flow cytometry?

yes no

15

Blood

yes no

16

Date sample collected:17 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

18

Specify percent disease detected:19 %

Bone marrow

yes no

20

Date sample collected:21 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

22

Specify percent disease detected:23 %

Were cytogenetics tested (karyotyping or FISH)? (at time of best response)

yes no Unknown

24

Were cytogenetics tested via FISH?

Yes No

25

Results of tests26

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities27

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

28

Specify other abnormality:29

Were cytogenetics tested via karyotyping?

Yes No

30

Results of tests31

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities32

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

33

Specify other abnormality:34

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

35

Was disease status assessed by other assessment?

Yes No

36

Date assessed:37 __ __ __ __ - __ __- __ __

Specify other assessment:38

Was disease detected?

yes no

39

Was the status considered a disease relapse?

yes no

40

Post-HCT / Post-InfusionTherapy Questions: 41 - 50

Was therapy given since the date of the last report for reasons other than relapse or persistent disease? (Include any maintenance and consolidation therapy.)

yes no

41

Central nervous system irradiation

yes no

42

Systemic therapy

yes no

43

Date therapy was first started44

Known

Unknown

Previously reported (e.g. started in/continuing from a prior reporting period)

Date first started:45 __ __ __ __ - __ __- __ __

Specify systemic therapy given (for reasons other than relapse or persistent disease (check all that apply)

Azacytidine

All-trans retinoic acid

Decitabine

Intrathecal therapy

Midostaurin

Sorafenib

Thioguanine

Other systemic therapy

46

(Vidaza)

(Tretinoin)

(Dacogen)

(6-TG)

Specify other systemic therapy:47

Cellular therapy (e.g. donor cellular infusions (DCI),CAR T-cells)48

yes -Also complete Pre-CTED form 4000

no

Other therapy

yes no

49

Specify other therapy:50

Disease Detection Since the Date of Last Report Questions: 51 - 103

Were tests for molecular markers performed? (and positive for disease) (e.g. PCR, NGS)

yes no Unknown

51

Date sample collected:52 __ __ __ __ - __ __- __ __

CEBPA

Positive Negative Not Done

53

Specify CEBPA mutation54

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

55

FLT3 – ITD mutation

Positive Negative Not Done

56

IDH1

Positive Negative Not Done

57

IDH2

Positive Negative Not Done

58

KIT

Positive Negative Not Done

59

NPM1

Positive Negative Not Done

60

Multiple Molecular Markers (1) Questions: 61 - 62

Other molecular marker

Positive Negative Not Done

61

Specify other molecular marker:62

Was disease detected via flow cytometry?

Yes No

63

Blood

yes no

64

Date sample collected:65 __ __ __ __ - __ __- __ __

Specify percent disease detected:66 %

Bone marrow

yes no

67

Date sample collected:68 __ __ __ __ - __ __- __ __

Specify percent disease detected:69 %

Was disease detected via cytogenetics testing? (karyotyping or FISH)

Yes No Unknown

70

Were cytogenetic abnormalities identified via FISH?

Yes No

71

Date sample collected:72 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

73

Specify other abnormality:74

Were cytogenetic abnormalities identified via karyotyping?

Yes No

75

Date sample collected:76 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

77

Specify other abnormality:78

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

79

Was disease detected by clinical / hematologic assessment?

Yes No

80

Date assessed:81 __ __ __ __ - __ __- __ __

Central nervous system

Yes No

82

Skin

yes no

83

Soft tissue

yes no

84

Other site

yes no

85

Specify other site:86

Was disease detected by other assessment?

Yes No

87

Date assessed:88 __ __ __ __ - __ __- __ __

Specify other assessment:89

Was intervention given for relapsed, persistent or progressive disease, or decreased/loss of chimerism since the date of last report?

Yes No

90

Intervention Given (1) Questions: 91 - 103

Specify reason for which intervention was given91

Minimal residual disease

Persistent disease

Relapsed disase

Central nervous system irradiation

yes no

92

Intrathecal therapy

yes no

93

Systemic therapy

yes no

94

Date therapy was first started95

Known

Unknown

Previously reported (e.g. started in a prior reporting period/continued from prior reporting period)

Date first started:96 __ __ __ __ - __ __- __ __

Specify systemic therapy given (check all that apply)

Azacytidine

All-trans retinoic acid

Arsenic

Cladribine

Clofarabine

Cytarabine (Ara ­ C) ≤ 10 g/m2/cycle

cytarabine (Ara - C) > 10 g/m2/cycle

Daunorubicin

Decitabine

Etoposide

Fludarabine

Gemtuzumab

Idarubicin

Midostaurin

Mitoxantrone

Sorafenib

Thioguanine

Other systemic therapy

97

(Vidaza)

(Tretinoin)

(2-CDA, Leustatin)

(Cerubidine)

(Dacogen) 

(VP-16, VePesid)

(Fludara)

(Mylotarg)

(Idamycin)

(Novantrone)

(6-TG)

Specify other systemic therapy:98

Cellular therapy (e.g. donor cellular infusions (DCI), CAR T-cells)99

yes -Also complete Pre-CTED form 4000

no

Subsequent HCT100

yes -Also complete Pre-TED form 2400

no

Accelerated withdrawal of immunosuppression in response to disease assessment

Yes No

101

Other therapy

yes no

102

Specify other therapy:103

Disease Status at the Time of Evaluation for this Reporting Period Questions: 104 - 145

Does the disease status reflect the disease detected in this reporting period section without subsequent therapy? (as captured in questions 51-89)

Yes No Not Applicable

104

Were tests for molecular markers performed? (e.g. PCR, NGS)

yes no Unknown

105

CEBPA

Positive Negative Not Done

106

Specify CEBPA mutation107

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

108

FLT3 – ITD mutation

Positive Negative Not Done

109

IDH1

Positive Negative Not Done

110

IDH2

Positive Negative Not Done

111

KIT

Positive Negative Not Done

112

NPM1

Positive Negative Not Done

113

Current Molecular Marker (1) Questions: 114 - 115

Other molecular marker

Positive Negative Not Done

114

Specify other molecular marker:115

Was the disease status assessed via flow cytometry?

yes no

116

Blood

yes no

117

Date sample collected:118 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

119

Specify percent disease detected:120 %

Bone marrow

yes no

121

Date sample collected:122 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

123

Specify percent disease detected:124 %

Were cytogenetics tested? (karyotyping or FISH)

yes no Unknown

125

Were cytogenetics tested via FISH?

yes no Unknown

126

Results of tests127

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities128

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

129

Specify other abnormality:130

Were cytogenetics tested via karyotyping?

Yes No Unknown

131

Results of tests132

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities133

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

134

Specify other abnormality:135

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

136

Was the disease status assessed by clinical / hematologic assessment?

yes no

137

Date assessed:138 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

139

Was disease status assessed by other assessment?

Yes No

140

Date assessed:141 __ __ __ __ - __ __- __ __

Specify other assessment:142

Was disease detected?

yes no

143

What is the current disease status?144

Complete remission (CR)

Not in complete remission

Date assessed:145 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Specify molecular markers identified at time of best response:

Specify tissue and results at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify therapy given:

Specify systemic therapy given for reasons other than relapse or persistent disease:

Specify molecular markers identified since the date of last report:

Specify tissue and results:

Specify site(s) of disease:

Specify the method(s) used to assess the disease status at the time of evaluation for this reporting period:

Specify molecular markers identified:

Specify tissue and results at the time of evaluation for this reporting period:

Specify cytogenetic abnormalities identified:

Specify cytogenetic abnormalities identified:

Center: CRID: 

Form 2110 R4.0: Acute Myelogenous Leukemia (AML) Post-Infusion Data

CIBMTR Form 2110 revision 4.0 last updated Wednesday, August 16, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 5 / 11



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Visit

100 day 6 months 1 year 2 years > 2 years,

Specify:

Disease Assessment at the Time of Best Response to HCT or Cellular Therapy Questions: 1 - 40

What was the best response to HCT or cellular therapy since the date of the last report? (Include response to any therapy given for post-HCT / post-infusion maintenance or
consolidation, but exclude any therapy given for relapsed, persistent, or progressive disease)

1

Continued complete remission (CCR) - For patients transplant in CR

Complete
remission (CR)

- All of the following response criteria without progression for at least four weeks: < 5% blasts in the bone marrow, no blasts with Auer rods, no
extramedullary disease (e.g., central nervous system or soft tissue involvement)

Not in complete remission

Was the date of best response previously reported?

yes no

2

Date assessed:3 __ __ __ __ - __ __- __ __

Were tests for molecular markers performed? (e.g. PCR, NGS) (at time of best response)

yes no Unknown

4

CEBPA

Positive Negative Not Done

5

Specify CEBPA mutation6

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

7

FLT3 – ITD mutation

Positive Negative Not Done

8

IDH1

Positive Negative Not Done

9

IDH2

Positive Negative Not Done

10

KIT

Positive Negative Not Done

11

NPM1

Positive Negative Not Done

12

Multiple Molecular Markers (1) Questions: 13 - 14

Other molecular marker

Positive Negative Not Done

13

Specify other molecular marker:14

Was the disease status assessed via flow cytometry?

yes no

15

Blood

yes no

16

Date sample collected:17 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

18

Specify percent disease detected:19 %

Bone marrow

yes no

20

Date sample collected:21 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

22

Specify percent disease detected:23 %

Were cytogenetics tested (karyotyping or FISH)? (at time of best response)

yes no Unknown

24

Were cytogenetics tested via FISH?

Yes No

25

Results of tests26

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities27

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

28

Specify other abnormality:29

Were cytogenetics tested via karyotyping?

Yes No

30

Results of tests31

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities32

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

33

Specify other abnormality:34

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

35

Was disease status assessed by other assessment?

Yes No

36

Date assessed:37 __ __ __ __ - __ __- __ __

Specify other assessment:38

Was disease detected?

yes no

39

Was the status considered a disease relapse?

yes no

40

Post-HCT / Post-InfusionTherapy Questions: 41 - 50

Was therapy given since the date of the last report for reasons other than relapse or persistent disease? (Include any maintenance and consolidation therapy.)

yes no

41

Central nervous system irradiation

yes no

42

Systemic therapy

yes no

43

Date therapy was first started44

Known

Unknown

Previously reported (e.g. started in/continuing from a prior reporting period)

Date first started:45 __ __ __ __ - __ __- __ __

Specify systemic therapy given (for reasons other than relapse or persistent disease (check all that apply)

Azacytidine

All-trans retinoic acid

Decitabine

Intrathecal therapy

Midostaurin

Sorafenib

Thioguanine

Other systemic therapy

46

(Vidaza)

(Tretinoin)

(Dacogen)

(6-TG)

Specify other systemic therapy:47

Cellular therapy (e.g. donor cellular infusions (DCI),CAR T-cells)48

yes -Also complete Pre-CTED form 4000

no

Other therapy

yes no

49

Specify other therapy:50

Disease Detection Since the Date of Last Report Questions: 51 - 103

Were tests for molecular markers performed? (and positive for disease) (e.g. PCR, NGS)

yes no Unknown

51

Date sample collected:52 __ __ __ __ - __ __- __ __

CEBPA

Positive Negative Not Done

53

Specify CEBPA mutation54

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

55

FLT3 – ITD mutation

Positive Negative Not Done

56

IDH1

Positive Negative Not Done

57

IDH2

Positive Negative Not Done

58

KIT

Positive Negative Not Done

59

NPM1

Positive Negative Not Done

60

Multiple Molecular Markers (1) Questions: 61 - 62

Other molecular marker

Positive Negative Not Done

61

Specify other molecular marker:62

Was disease detected via flow cytometry?

Yes No

63

Blood

yes no

64

Date sample collected:65 __ __ __ __ - __ __- __ __

Specify percent disease detected:66 %

Bone marrow

yes no

67

Date sample collected:68 __ __ __ __ - __ __- __ __

Specify percent disease detected:69 %

Was disease detected via cytogenetics testing? (karyotyping or FISH)

Yes No Unknown

70

Were cytogenetic abnormalities identified via FISH?

Yes No

71

Date sample collected:72 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

73

Specify other abnormality:74

Were cytogenetic abnormalities identified via karyotyping?

Yes No

75

Date sample collected:76 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

77

Specify other abnormality:78

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

79

Was disease detected by clinical / hematologic assessment?

Yes No

80

Date assessed:81 __ __ __ __ - __ __- __ __

Central nervous system

Yes No

82

Skin

yes no

83

Soft tissue

yes no

84

Other site

yes no

85

Specify other site:86

Was disease detected by other assessment?

Yes No

87

Date assessed:88 __ __ __ __ - __ __- __ __

Specify other assessment:89

Was intervention given for relapsed, persistent or progressive disease, or decreased/loss of chimerism since the date of last report?

Yes No

90

Intervention Given (1) Questions: 91 - 103

Specify reason for which intervention was given91

Minimal residual disease

Persistent disease

Relapsed disase

Central nervous system irradiation

yes no

92

Intrathecal therapy

yes no

93

Systemic therapy

yes no

94

Date therapy was first started95

Known

Unknown

Previously reported (e.g. started in a prior reporting period/continued from prior reporting period)

Date first started:96 __ __ __ __ - __ __- __ __

Specify systemic therapy given (check all that apply)

Azacytidine

All-trans retinoic acid

Arsenic

Cladribine

Clofarabine

Cytarabine (Ara ­ C) ≤ 10 g/m2/cycle

cytarabine (Ara - C) > 10 g/m2/cycle

Daunorubicin

Decitabine

Etoposide

Fludarabine

Gemtuzumab

Idarubicin

Midostaurin

Mitoxantrone

Sorafenib

Thioguanine

Other systemic therapy

97

(Vidaza)

(Tretinoin)

(2-CDA, Leustatin)

(Cerubidine)

(Dacogen) 

(VP-16, VePesid)

(Fludara)

(Mylotarg)

(Idamycin)

(Novantrone)

(6-TG)

Specify other systemic therapy:98

Cellular therapy (e.g. donor cellular infusions (DCI), CAR T-cells)99

yes -Also complete Pre-CTED form 4000

no

Subsequent HCT100

yes -Also complete Pre-TED form 2400

no

Accelerated withdrawal of immunosuppression in response to disease assessment

Yes No

101

Other therapy

yes no

102

Specify other therapy:103

Disease Status at the Time of Evaluation for this Reporting Period Questions: 104 - 145

Does the disease status reflect the disease detected in this reporting period section without subsequent therapy? (as captured in questions 51-89)

Yes No Not Applicable

104

Were tests for molecular markers performed? (e.g. PCR, NGS)

yes no Unknown

105

CEBPA

Positive Negative Not Done

106

Specify CEBPA mutation107

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

108

FLT3 – ITD mutation

Positive Negative Not Done

109

IDH1

Positive Negative Not Done

110

IDH2

Positive Negative Not Done

111

KIT

Positive Negative Not Done

112

NPM1

Positive Negative Not Done

113

Current Molecular Marker (1) Questions: 114 - 115

Other molecular marker

Positive Negative Not Done

114

Specify other molecular marker:115

Was the disease status assessed via flow cytometry?

yes no

116

Blood

yes no

117

Date sample collected:118 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

119

Specify percent disease detected:120 %

Bone marrow

yes no

121

Date sample collected:122 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

123

Specify percent disease detected:124 %

Were cytogenetics tested? (karyotyping or FISH)

yes no Unknown

125

Were cytogenetics tested via FISH?

yes no Unknown

126

Results of tests127

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities128

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

129

Specify other abnormality:130

Were cytogenetics tested via karyotyping?

Yes No Unknown

131

Results of tests132

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities133

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

134

Specify other abnormality:135

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

136

Was the disease status assessed by clinical / hematologic assessment?

yes no

137

Date assessed:138 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

139

Was disease status assessed by other assessment?

Yes No

140

Date assessed:141 __ __ __ __ - __ __- __ __

Specify other assessment:142

Was disease detected?

yes no

143

What is the current disease status?144

Complete remission (CR)

Not in complete remission

Date assessed:145 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Specify molecular markers identified at time of best response:

Specify tissue and results at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify therapy given:

Specify systemic therapy given for reasons other than relapse or persistent disease:

Specify molecular markers identified since the date of last report:

Specify tissue and results:

Specify site(s) of disease:

Specify the method(s) used to assess the disease status at the time of evaluation for this reporting period:

Specify molecular markers identified:

Specify tissue and results at the time of evaluation for this reporting period:

Specify cytogenetic abnormalities identified:

Specify cytogenetic abnormalities identified:

Center: CRID: 

Form 2110 R4.0: Acute Myelogenous Leukemia (AML) Post-Infusion Data

CIBMTR Form 2110 revision 4.0 last updated Wednesday, August 16, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 6 / 11



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Visit

100 day 6 months 1 year 2 years > 2 years,

Specify:

Disease Assessment at the Time of Best Response to HCT or Cellular Therapy Questions: 1 - 40

What was the best response to HCT or cellular therapy since the date of the last report? (Include response to any therapy given for post-HCT / post-infusion maintenance or
consolidation, but exclude any therapy given for relapsed, persistent, or progressive disease)

1

Continued complete remission (CCR) - For patients transplant in CR

Complete
remission (CR)

- All of the following response criteria without progression for at least four weeks: < 5% blasts in the bone marrow, no blasts with Auer rods, no
extramedullary disease (e.g., central nervous system or soft tissue involvement)

Not in complete remission

Was the date of best response previously reported?

yes no

2

Date assessed:3 __ __ __ __ - __ __- __ __

Were tests for molecular markers performed? (e.g. PCR, NGS) (at time of best response)

yes no Unknown

4

CEBPA

Positive Negative Not Done

5

Specify CEBPA mutation6

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

7

FLT3 – ITD mutation

Positive Negative Not Done

8

IDH1

Positive Negative Not Done

9

IDH2

Positive Negative Not Done

10

KIT

Positive Negative Not Done

11

NPM1

Positive Negative Not Done

12

Multiple Molecular Markers (1) Questions: 13 - 14

Other molecular marker

Positive Negative Not Done

13

Specify other molecular marker:14

Was the disease status assessed via flow cytometry?

yes no

15

Blood

yes no

16

Date sample collected:17 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

18

Specify percent disease detected:19 %

Bone marrow

yes no

20

Date sample collected:21 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

22

Specify percent disease detected:23 %

Were cytogenetics tested (karyotyping or FISH)? (at time of best response)

yes no Unknown

24

Were cytogenetics tested via FISH?

Yes No

25

Results of tests26

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities27

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

28

Specify other abnormality:29

Were cytogenetics tested via karyotyping?

Yes No

30

Results of tests31

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities32

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

33

Specify other abnormality:34

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

35

Was disease status assessed by other assessment?

Yes No

36

Date assessed:37 __ __ __ __ - __ __- __ __

Specify other assessment:38

Was disease detected?

yes no

39

Was the status considered a disease relapse?

yes no

40

Post-HCT / Post-InfusionTherapy Questions: 41 - 50

Was therapy given since the date of the last report for reasons other than relapse or persistent disease? (Include any maintenance and consolidation therapy.)

yes no

41

Central nervous system irradiation

yes no

42

Systemic therapy

yes no

43

Date therapy was first started44

Known

Unknown

Previously reported (e.g. started in/continuing from a prior reporting period)

Date first started:45 __ __ __ __ - __ __- __ __

Specify systemic therapy given (for reasons other than relapse or persistent disease (check all that apply)

Azacytidine

All-trans retinoic acid

Decitabine

Intrathecal therapy

Midostaurin

Sorafenib

Thioguanine

Other systemic therapy

46

(Vidaza)

(Tretinoin)

(Dacogen)

(6-TG)

Specify other systemic therapy:47

Cellular therapy (e.g. donor cellular infusions (DCI),CAR T-cells)48

yes -Also complete Pre-CTED form 4000

no

Other therapy

yes no

49

Specify other therapy:50

Disease Detection Since the Date of Last Report Questions: 51 - 103

Were tests for molecular markers performed? (and positive for disease) (e.g. PCR, NGS)

yes no Unknown

51

Date sample collected:52 __ __ __ __ - __ __- __ __

CEBPA

Positive Negative Not Done

53

Specify CEBPA mutation54

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

55

FLT3 – ITD mutation

Positive Negative Not Done

56

IDH1

Positive Negative Not Done

57

IDH2

Positive Negative Not Done

58

KIT

Positive Negative Not Done

59

NPM1

Positive Negative Not Done

60

Multiple Molecular Markers (1) Questions: 61 - 62

Other molecular marker

Positive Negative Not Done

61

Specify other molecular marker:62

Was disease detected via flow cytometry?

Yes No

63

Blood

yes no

64

Date sample collected:65 __ __ __ __ - __ __- __ __

Specify percent disease detected:66 %

Bone marrow

yes no

67

Date sample collected:68 __ __ __ __ - __ __- __ __

Specify percent disease detected:69 %

Was disease detected via cytogenetics testing? (karyotyping or FISH)

Yes No Unknown

70

Were cytogenetic abnormalities identified via FISH?

Yes No

71

Date sample collected:72 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

73

Specify other abnormality:74

Were cytogenetic abnormalities identified via karyotyping?

Yes No

75

Date sample collected:76 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

77

Specify other abnormality:78

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

79

Was disease detected by clinical / hematologic assessment?

Yes No

80

Date assessed:81 __ __ __ __ - __ __- __ __

Central nervous system

Yes No

82

Skin

yes no

83

Soft tissue

yes no

84

Other site

yes no

85

Specify other site:86

Was disease detected by other assessment?

Yes No

87

Date assessed:88 __ __ __ __ - __ __- __ __

Specify other assessment:89

Was intervention given for relapsed, persistent or progressive disease, or decreased/loss of chimerism since the date of last report?

Yes No

90

Intervention Given (1) Questions: 91 - 103

Specify reason for which intervention was given91

Minimal residual disease

Persistent disease

Relapsed disase

Central nervous system irradiation

yes no

92

Intrathecal therapy

yes no

93

Systemic therapy

yes no

94

Date therapy was first started95

Known

Unknown

Previously reported (e.g. started in a prior reporting period/continued from prior reporting period)

Date first started:96 __ __ __ __ - __ __- __ __

Specify systemic therapy given (check all that apply)

Azacytidine

All-trans retinoic acid

Arsenic

Cladribine

Clofarabine

Cytarabine (Ara ­ C) ≤ 10 g/m2/cycle

cytarabine (Ara - C) > 10 g/m2/cycle

Daunorubicin

Decitabine

Etoposide

Fludarabine

Gemtuzumab

Idarubicin

Midostaurin

Mitoxantrone

Sorafenib

Thioguanine

Other systemic therapy

97

(Vidaza)

(Tretinoin)

(2-CDA, Leustatin)

(Cerubidine)

(Dacogen) 

(VP-16, VePesid)

(Fludara)

(Mylotarg)

(Idamycin)

(Novantrone)

(6-TG)

Specify other systemic therapy:98

Cellular therapy (e.g. donor cellular infusions (DCI), CAR T-cells)99

yes -Also complete Pre-CTED form 4000

no

Subsequent HCT100

yes -Also complete Pre-TED form 2400

no

Accelerated withdrawal of immunosuppression in response to disease assessment

Yes No

101

Other therapy

yes no

102

Specify other therapy:103

Disease Status at the Time of Evaluation for this Reporting Period Questions: 104 - 145

Does the disease status reflect the disease detected in this reporting period section without subsequent therapy? (as captured in questions 51-89)

Yes No Not Applicable

104

Were tests for molecular markers performed? (e.g. PCR, NGS)

yes no Unknown

105

CEBPA

Positive Negative Not Done

106

Specify CEBPA mutation107

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

108

FLT3 – ITD mutation

Positive Negative Not Done

109

IDH1

Positive Negative Not Done

110

IDH2

Positive Negative Not Done

111

KIT

Positive Negative Not Done

112

NPM1

Positive Negative Not Done

113

Current Molecular Marker (1) Questions: 114 - 115

Other molecular marker

Positive Negative Not Done

114

Specify other molecular marker:115

Was the disease status assessed via flow cytometry?

yes no

116

Blood

yes no

117

Date sample collected:118 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

119

Specify percent disease detected:120 %

Bone marrow

yes no

121

Date sample collected:122 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

123

Specify percent disease detected:124 %

Were cytogenetics tested? (karyotyping or FISH)

yes no Unknown

125

Were cytogenetics tested via FISH?

yes no Unknown

126

Results of tests127

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities128

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

129

Specify other abnormality:130

Were cytogenetics tested via karyotyping?

Yes No Unknown

131

Results of tests132

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities133

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

134

Specify other abnormality:135

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

136

Was the disease status assessed by clinical / hematologic assessment?

yes no

137

Date assessed:138 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

139

Was disease status assessed by other assessment?

Yes No

140

Date assessed:141 __ __ __ __ - __ __- __ __

Specify other assessment:142

Was disease detected?

yes no

143

What is the current disease status?144

Complete remission (CR)

Not in complete remission

Date assessed:145 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Specify molecular markers identified at time of best response:

Specify tissue and results at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify therapy given:

Specify systemic therapy given for reasons other than relapse or persistent disease:

Specify molecular markers identified since the date of last report:

Specify tissue and results:

Specify site(s) of disease:

Specify the method(s) used to assess the disease status at the time of evaluation for this reporting period:

Specify molecular markers identified:

Specify tissue and results at the time of evaluation for this reporting period:

Specify cytogenetic abnormalities identified:

Specify cytogenetic abnormalities identified:

Center: CRID: 

Form 2110 R4.0: Acute Myelogenous Leukemia (AML) Post-Infusion Data

CIBMTR Form 2110 revision 4.0 last updated Wednesday, August 16, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 7 / 11



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Visit

100 day 6 months 1 year 2 years > 2 years,

Specify:

Disease Assessment at the Time of Best Response to HCT or Cellular Therapy Questions: 1 - 40

What was the best response to HCT or cellular therapy since the date of the last report? (Include response to any therapy given for post-HCT / post-infusion maintenance or
consolidation, but exclude any therapy given for relapsed, persistent, or progressive disease)

1

Continued complete remission (CCR) - For patients transplant in CR

Complete
remission (CR)

- All of the following response criteria without progression for at least four weeks: < 5% blasts in the bone marrow, no blasts with Auer rods, no
extramedullary disease (e.g., central nervous system or soft tissue involvement)

Not in complete remission

Was the date of best response previously reported?

yes no

2

Date assessed:3 __ __ __ __ - __ __- __ __

Were tests for molecular markers performed? (e.g. PCR, NGS) (at time of best response)

yes no Unknown

4

CEBPA

Positive Negative Not Done

5

Specify CEBPA mutation6

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

7

FLT3 – ITD mutation

Positive Negative Not Done

8

IDH1

Positive Negative Not Done

9

IDH2

Positive Negative Not Done

10

KIT

Positive Negative Not Done

11

NPM1

Positive Negative Not Done

12

Multiple Molecular Markers (1) Questions: 13 - 14

Other molecular marker

Positive Negative Not Done

13

Specify other molecular marker:14

Was the disease status assessed via flow cytometry?

yes no

15

Blood

yes no

16

Date sample collected:17 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

18

Specify percent disease detected:19 %

Bone marrow

yes no

20

Date sample collected:21 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

22

Specify percent disease detected:23 %

Were cytogenetics tested (karyotyping or FISH)? (at time of best response)

yes no Unknown

24

Were cytogenetics tested via FISH?

Yes No

25

Results of tests26

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities27

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

28

Specify other abnormality:29

Were cytogenetics tested via karyotyping?

Yes No

30

Results of tests31

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities32

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

33

Specify other abnormality:34

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

35

Was disease status assessed by other assessment?

Yes No

36

Date assessed:37 __ __ __ __ - __ __- __ __

Specify other assessment:38

Was disease detected?

yes no

39

Was the status considered a disease relapse?

yes no

40

Post-HCT / Post-InfusionTherapy Questions: 41 - 50

Was therapy given since the date of the last report for reasons other than relapse or persistent disease? (Include any maintenance and consolidation therapy.)

yes no

41

Central nervous system irradiation

yes no

42

Systemic therapy

yes no

43

Date therapy was first started44

Known

Unknown

Previously reported (e.g. started in/continuing from a prior reporting period)

Date first started:45 __ __ __ __ - __ __- __ __

Specify systemic therapy given (for reasons other than relapse or persistent disease (check all that apply)

Azacytidine

All-trans retinoic acid

Decitabine

Intrathecal therapy

Midostaurin

Sorafenib

Thioguanine

Other systemic therapy

46

(Vidaza)

(Tretinoin)

(Dacogen)

(6-TG)

Specify other systemic therapy:47

Cellular therapy (e.g. donor cellular infusions (DCI),CAR T-cells)48

yes -Also complete Pre-CTED form 4000

no

Other therapy

yes no

49

Specify other therapy:50

Disease Detection Since the Date of Last Report Questions: 51 - 103

Were tests for molecular markers performed? (and positive for disease) (e.g. PCR, NGS)

yes no Unknown

51

Date sample collected:52 __ __ __ __ - __ __- __ __

CEBPA

Positive Negative Not Done

53

Specify CEBPA mutation54

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

55

FLT3 – ITD mutation

Positive Negative Not Done

56

IDH1

Positive Negative Not Done

57

IDH2

Positive Negative Not Done

58

KIT

Positive Negative Not Done

59

NPM1

Positive Negative Not Done

60

Multiple Molecular Markers (1) Questions: 61 - 62

Other molecular marker

Positive Negative Not Done

61

Specify other molecular marker:62

Was disease detected via flow cytometry?

Yes No

63

Blood

yes no

64

Date sample collected:65 __ __ __ __ - __ __- __ __

Specify percent disease detected:66 %

Bone marrow

yes no

67

Date sample collected:68 __ __ __ __ - __ __- __ __

Specify percent disease detected:69 %

Was disease detected via cytogenetics testing? (karyotyping or FISH)

Yes No Unknown

70

Were cytogenetic abnormalities identified via FISH?

Yes No

71

Date sample collected:72 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

73

Specify other abnormality:74

Were cytogenetic abnormalities identified via karyotyping?

Yes No

75

Date sample collected:76 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

77

Specify other abnormality:78

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

79

Was disease detected by clinical / hematologic assessment?

Yes No

80

Date assessed:81 __ __ __ __ - __ __- __ __

Central nervous system

Yes No

82

Skin

yes no

83

Soft tissue

yes no

84

Other site

yes no

85

Specify other site:86

Was disease detected by other assessment?

Yes No

87

Date assessed:88 __ __ __ __ - __ __- __ __

Specify other assessment:89

Was intervention given for relapsed, persistent or progressive disease, or decreased/loss of chimerism since the date of last report?

Yes No

90

Intervention Given (1) Questions: 91 - 103

Specify reason for which intervention was given91

Minimal residual disease

Persistent disease

Relapsed disase

Central nervous system irradiation

yes no

92

Intrathecal therapy

yes no

93

Systemic therapy

yes no

94

Date therapy was first started95

Known

Unknown

Previously reported (e.g. started in a prior reporting period/continued from prior reporting period)

Date first started:96 __ __ __ __ - __ __- __ __

Specify systemic therapy given (check all that apply)

Azacytidine

All-trans retinoic acid

Arsenic

Cladribine

Clofarabine

Cytarabine (Ara ­ C) ≤ 10 g/m2/cycle

cytarabine (Ara - C) > 10 g/m2/cycle

Daunorubicin

Decitabine

Etoposide

Fludarabine

Gemtuzumab

Idarubicin

Midostaurin

Mitoxantrone

Sorafenib

Thioguanine

Other systemic therapy

97

(Vidaza)

(Tretinoin)

(2-CDA, Leustatin)

(Cerubidine)

(Dacogen) 

(VP-16, VePesid)

(Fludara)

(Mylotarg)

(Idamycin)

(Novantrone)

(6-TG)

Specify other systemic therapy:98

Cellular therapy (e.g. donor cellular infusions (DCI), CAR T-cells)99

yes -Also complete Pre-CTED form 4000

no

Subsequent HCT100

yes -Also complete Pre-TED form 2400

no

Accelerated withdrawal of immunosuppression in response to disease assessment

Yes No

101

Other therapy

yes no

102

Specify other therapy:103

Disease Status at the Time of Evaluation for this Reporting Period Questions: 104 - 145

Does the disease status reflect the disease detected in this reporting period section without subsequent therapy? (as captured in questions 51-89)

Yes No Not Applicable

104

Were tests for molecular markers performed? (e.g. PCR, NGS)

yes no Unknown

105

CEBPA

Positive Negative Not Done

106

Specify CEBPA mutation107

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

108

FLT3 – ITD mutation

Positive Negative Not Done

109

IDH1

Positive Negative Not Done

110

IDH2

Positive Negative Not Done

111

KIT

Positive Negative Not Done

112

NPM1

Positive Negative Not Done

113

Current Molecular Marker (1) Questions: 114 - 115

Other molecular marker

Positive Negative Not Done

114

Specify other molecular marker:115

Was the disease status assessed via flow cytometry?

yes no

116

Blood

yes no

117

Date sample collected:118 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

119

Specify percent disease detected:120 %

Bone marrow

yes no

121

Date sample collected:122 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

123

Specify percent disease detected:124 %

Were cytogenetics tested? (karyotyping or FISH)

yes no Unknown

125

Were cytogenetics tested via FISH?

yes no Unknown

126

Results of tests127

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities128

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

129

Specify other abnormality:130

Were cytogenetics tested via karyotyping?

Yes No Unknown

131

Results of tests132

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities133

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

134

Specify other abnormality:135

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

136

Was the disease status assessed by clinical / hematologic assessment?

yes no

137

Date assessed:138 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

139

Was disease status assessed by other assessment?

Yes No

140

Date assessed:141 __ __ __ __ - __ __- __ __

Specify other assessment:142

Was disease detected?

yes no

143

What is the current disease status?144

Complete remission (CR)

Not in complete remission

Date assessed:145 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Specify molecular markers identified at time of best response:

Specify tissue and results at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify therapy given:

Specify systemic therapy given for reasons other than relapse or persistent disease:

Specify molecular markers identified since the date of last report:

Specify tissue and results:

Specify site(s) of disease:

Specify the method(s) used to assess the disease status at the time of evaluation for this reporting period:

Specify molecular markers identified:

Specify tissue and results at the time of evaluation for this reporting period:

Specify cytogenetic abnormalities identified:

Specify cytogenetic abnormalities identified:

Center: CRID: 

Form 2110 R4.0: Acute Myelogenous Leukemia (AML) Post-Infusion Data

CIBMTR Form 2110 revision 4.0 last updated Wednesday, August 16, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 8 / 11



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Visit

100 day 6 months 1 year 2 years > 2 years,

Specify:

Disease Assessment at the Time of Best Response to HCT or Cellular Therapy Questions: 1 - 40

What was the best response to HCT or cellular therapy since the date of the last report? (Include response to any therapy given for post-HCT / post-infusion maintenance or
consolidation, but exclude any therapy given for relapsed, persistent, or progressive disease)

1

Continued complete remission (CCR) - For patients transplant in CR

Complete
remission (CR)

- All of the following response criteria without progression for at least four weeks: < 5% blasts in the bone marrow, no blasts with Auer rods, no
extramedullary disease (e.g., central nervous system or soft tissue involvement)

Not in complete remission

Was the date of best response previously reported?

yes no

2

Date assessed:3 __ __ __ __ - __ __- __ __

Were tests for molecular markers performed? (e.g. PCR, NGS) (at time of best response)

yes no Unknown

4

CEBPA

Positive Negative Not Done

5

Specify CEBPA mutation6

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

7

FLT3 – ITD mutation

Positive Negative Not Done

8

IDH1

Positive Negative Not Done

9

IDH2

Positive Negative Not Done

10

KIT

Positive Negative Not Done

11

NPM1

Positive Negative Not Done

12

Multiple Molecular Markers (1) Questions: 13 - 14

Other molecular marker

Positive Negative Not Done

13

Specify other molecular marker:14

Was the disease status assessed via flow cytometry?

yes no

15

Blood

yes no

16

Date sample collected:17 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

18

Specify percent disease detected:19 %

Bone marrow

yes no

20

Date sample collected:21 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

22

Specify percent disease detected:23 %

Were cytogenetics tested (karyotyping or FISH)? (at time of best response)

yes no Unknown

24

Were cytogenetics tested via FISH?

Yes No

25

Results of tests26

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities27

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

28

Specify other abnormality:29

Were cytogenetics tested via karyotyping?

Yes No

30

Results of tests31

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities32

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

33

Specify other abnormality:34

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

35

Was disease status assessed by other assessment?

Yes No

36

Date assessed:37 __ __ __ __ - __ __- __ __

Specify other assessment:38

Was disease detected?

yes no

39

Was the status considered a disease relapse?

yes no

40

Post-HCT / Post-InfusionTherapy Questions: 41 - 50

Was therapy given since the date of the last report for reasons other than relapse or persistent disease? (Include any maintenance and consolidation therapy.)

yes no

41

Central nervous system irradiation

yes no

42

Systemic therapy

yes no

43

Date therapy was first started44

Known

Unknown

Previously reported (e.g. started in/continuing from a prior reporting period)

Date first started:45 __ __ __ __ - __ __- __ __

Specify systemic therapy given (for reasons other than relapse or persistent disease (check all that apply)

Azacytidine

All-trans retinoic acid

Decitabine

Intrathecal therapy

Midostaurin

Sorafenib

Thioguanine

Other systemic therapy

46

(Vidaza)

(Tretinoin)

(Dacogen)

(6-TG)

Specify other systemic therapy:47

Cellular therapy (e.g. donor cellular infusions (DCI),CAR T-cells)48

yes -Also complete Pre-CTED form 4000

no

Other therapy

yes no

49

Specify other therapy:50

Disease Detection Since the Date of Last Report Questions: 51 - 103

Were tests for molecular markers performed? (and positive for disease) (e.g. PCR, NGS)

yes no Unknown

51

Date sample collected:52 __ __ __ __ - __ __- __ __

CEBPA

Positive Negative Not Done

53

Specify CEBPA mutation54

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

55

FLT3 – ITD mutation

Positive Negative Not Done

56

IDH1

Positive Negative Not Done

57

IDH2

Positive Negative Not Done

58

KIT

Positive Negative Not Done

59

NPM1

Positive Negative Not Done

60

Multiple Molecular Markers (1) Questions: 61 - 62

Other molecular marker

Positive Negative Not Done

61

Specify other molecular marker:62

Was disease detected via flow cytometry?

Yes No

63

Blood

yes no

64

Date sample collected:65 __ __ __ __ - __ __- __ __

Specify percent disease detected:66 %

Bone marrow

yes no

67

Date sample collected:68 __ __ __ __ - __ __- __ __

Specify percent disease detected:69 %

Was disease detected via cytogenetics testing? (karyotyping or FISH)

Yes No Unknown

70

Were cytogenetic abnormalities identified via FISH?

Yes No

71

Date sample collected:72 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

73

Specify other abnormality:74

Were cytogenetic abnormalities identified via karyotyping?

Yes No

75

Date sample collected:76 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

77

Specify other abnormality:78

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

79

Was disease detected by clinical / hematologic assessment?

Yes No

80

Date assessed:81 __ __ __ __ - __ __- __ __

Central nervous system

Yes No

82

Skin

yes no

83

Soft tissue

yes no

84

Other site

yes no

85

Specify other site:86

Was disease detected by other assessment?

Yes No

87

Date assessed:88 __ __ __ __ - __ __- __ __

Specify other assessment:89

Was intervention given for relapsed, persistent or progressive disease, or decreased/loss of chimerism since the date of last report?

Yes No

90

Intervention Given (1) Questions: 91 - 103

Specify reason for which intervention was given91

Minimal residual disease

Persistent disease

Relapsed disase

Central nervous system irradiation

yes no

92

Intrathecal therapy

yes no

93

Systemic therapy

yes no

94

Date therapy was first started95

Known

Unknown

Previously reported (e.g. started in a prior reporting period/continued from prior reporting period)

Date first started:96 __ __ __ __ - __ __- __ __

Specify systemic therapy given (check all that apply)

Azacytidine

All-trans retinoic acid

Arsenic

Cladribine

Clofarabine

Cytarabine (Ara ­ C) ≤ 10 g/m2/cycle

cytarabine (Ara - C) > 10 g/m2/cycle

Daunorubicin

Decitabine

Etoposide

Fludarabine

Gemtuzumab

Idarubicin

Midostaurin

Mitoxantrone

Sorafenib

Thioguanine

Other systemic therapy

97

(Vidaza)

(Tretinoin)

(2-CDA, Leustatin)

(Cerubidine)

(Dacogen) 

(VP-16, VePesid)

(Fludara)

(Mylotarg)

(Idamycin)

(Novantrone)

(6-TG)

Specify other systemic therapy:98

Cellular therapy (e.g. donor cellular infusions (DCI), CAR T-cells)99

yes -Also complete Pre-CTED form 4000

no

Subsequent HCT100

yes -Also complete Pre-TED form 2400

no

Accelerated withdrawal of immunosuppression in response to disease assessment

Yes No

101

Other therapy

yes no

102

Specify other therapy:103

Disease Status at the Time of Evaluation for this Reporting Period Questions: 104 - 145

Does the disease status reflect the disease detected in this reporting period section without subsequent therapy? (as captured in questions 51-89)

Yes No Not Applicable

104

Were tests for molecular markers performed? (e.g. PCR, NGS)

yes no Unknown

105

CEBPA

Positive Negative Not Done

106

Specify CEBPA mutation107

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

108

FLT3 – ITD mutation

Positive Negative Not Done

109

IDH1

Positive Negative Not Done

110

IDH2

Positive Negative Not Done

111

KIT

Positive Negative Not Done

112

NPM1

Positive Negative Not Done

113

Current Molecular Marker (1) Questions: 114 - 115

Other molecular marker

Positive Negative Not Done

114

Specify other molecular marker:115

Was the disease status assessed via flow cytometry?

yes no

116

Blood

yes no

117

Date sample collected:118 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

119

Specify percent disease detected:120 %

Bone marrow

yes no

121

Date sample collected:122 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

123

Specify percent disease detected:124 %

Were cytogenetics tested? (karyotyping or FISH)

yes no Unknown

125

Were cytogenetics tested via FISH?

yes no Unknown

126

Results of tests127

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities128

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

129

Specify other abnormality:130

Were cytogenetics tested via karyotyping?

Yes No Unknown

131

Results of tests132

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities133

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

134

Specify other abnormality:135

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

136

Was the disease status assessed by clinical / hematologic assessment?

yes no

137

Date assessed:138 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

139

Was disease status assessed by other assessment?

Yes No

140

Date assessed:141 __ __ __ __ - __ __- __ __

Specify other assessment:142

Was disease detected?

yes no

143

What is the current disease status?144

Complete remission (CR)

Not in complete remission

Date assessed:145 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Specify molecular markers identified at time of best response:

Specify tissue and results at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify therapy given:

Specify systemic therapy given for reasons other than relapse or persistent disease:

Specify molecular markers identified since the date of last report:

Specify tissue and results:

Specify site(s) of disease:

Specify the method(s) used to assess the disease status at the time of evaluation for this reporting period:

Specify molecular markers identified:

Specify tissue and results at the time of evaluation for this reporting period:

Specify cytogenetic abnormalities identified:

Specify cytogenetic abnormalities identified:

Center: CRID: 

Form 2110 R4.0: Acute Myelogenous Leukemia (AML) Post-Infusion Data

CIBMTR Form 2110 revision 4.0 last updated Wednesday, August 16, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 9 / 11



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Visit

100 day 6 months 1 year 2 years > 2 years,

Specify:

Disease Assessment at the Time of Best Response to HCT or Cellular Therapy Questions: 1 - 40

What was the best response to HCT or cellular therapy since the date of the last report? (Include response to any therapy given for post-HCT / post-infusion maintenance or
consolidation, but exclude any therapy given for relapsed, persistent, or progressive disease)

1

Continued complete remission (CCR) - For patients transplant in CR

Complete
remission (CR)

- All of the following response criteria without progression for at least four weeks: < 5% blasts in the bone marrow, no blasts with Auer rods, no
extramedullary disease (e.g., central nervous system or soft tissue involvement)

Not in complete remission

Was the date of best response previously reported?

yes no

2

Date assessed:3 __ __ __ __ - __ __- __ __

Were tests for molecular markers performed? (e.g. PCR, NGS) (at time of best response)

yes no Unknown

4

CEBPA

Positive Negative Not Done

5

Specify CEBPA mutation6

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

7

FLT3 – ITD mutation

Positive Negative Not Done

8

IDH1

Positive Negative Not Done

9

IDH2

Positive Negative Not Done

10

KIT

Positive Negative Not Done

11

NPM1

Positive Negative Not Done

12

Multiple Molecular Markers (1) Questions: 13 - 14

Other molecular marker

Positive Negative Not Done

13

Specify other molecular marker:14

Was the disease status assessed via flow cytometry?

yes no

15

Blood

yes no

16

Date sample collected:17 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

18

Specify percent disease detected:19 %

Bone marrow

yes no

20

Date sample collected:21 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

22

Specify percent disease detected:23 %

Were cytogenetics tested (karyotyping or FISH)? (at time of best response)

yes no Unknown

24

Were cytogenetics tested via FISH?

Yes No

25

Results of tests26

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities27

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

28

Specify other abnormality:29

Were cytogenetics tested via karyotyping?

Yes No

30

Results of tests31

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities32

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

33

Specify other abnormality:34

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

35

Was disease status assessed by other assessment?

Yes No

36

Date assessed:37 __ __ __ __ - __ __- __ __

Specify other assessment:38

Was disease detected?

yes no

39

Was the status considered a disease relapse?

yes no

40

Post-HCT / Post-InfusionTherapy Questions: 41 - 50

Was therapy given since the date of the last report for reasons other than relapse or persistent disease? (Include any maintenance and consolidation therapy.)

yes no

41

Central nervous system irradiation

yes no

42

Systemic therapy

yes no

43

Date therapy was first started44

Known

Unknown

Previously reported (e.g. started in/continuing from a prior reporting period)

Date first started:45 __ __ __ __ - __ __- __ __

Specify systemic therapy given (for reasons other than relapse or persistent disease (check all that apply)

Azacytidine

All-trans retinoic acid

Decitabine

Intrathecal therapy

Midostaurin

Sorafenib

Thioguanine

Other systemic therapy

46

(Vidaza)

(Tretinoin)

(Dacogen)

(6-TG)

Specify other systemic therapy:47

Cellular therapy (e.g. donor cellular infusions (DCI),CAR T-cells)48

yes -Also complete Pre-CTED form 4000

no

Other therapy

yes no

49

Specify other therapy:50

Disease Detection Since the Date of Last Report Questions: 51 - 103

Were tests for molecular markers performed? (and positive for disease) (e.g. PCR, NGS)

yes no Unknown

51

Date sample collected:52 __ __ __ __ - __ __- __ __

CEBPA

Positive Negative Not Done

53

Specify CEBPA mutation54

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

55

FLT3 – ITD mutation

Positive Negative Not Done

56

IDH1

Positive Negative Not Done

57

IDH2

Positive Negative Not Done

58

KIT

Positive Negative Not Done

59

NPM1

Positive Negative Not Done

60

Multiple Molecular Markers (1) Questions: 61 - 62

Other molecular marker

Positive Negative Not Done

61

Specify other molecular marker:62

Was disease detected via flow cytometry?

Yes No

63

Blood

yes no

64

Date sample collected:65 __ __ __ __ - __ __- __ __

Specify percent disease detected:66 %

Bone marrow

yes no

67

Date sample collected:68 __ __ __ __ - __ __- __ __

Specify percent disease detected:69 %

Was disease detected via cytogenetics testing? (karyotyping or FISH)

Yes No Unknown

70

Were cytogenetic abnormalities identified via FISH?

Yes No

71

Date sample collected:72 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

73

Specify other abnormality:74

Were cytogenetic abnormalities identified via karyotyping?

Yes No

75

Date sample collected:76 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

77

Specify other abnormality:78

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

79

Was disease detected by clinical / hematologic assessment?

Yes No

80

Date assessed:81 __ __ __ __ - __ __- __ __

Central nervous system

Yes No

82

Skin

yes no

83

Soft tissue

yes no

84

Other site

yes no

85

Specify other site:86

Was disease detected by other assessment?

Yes No

87

Date assessed:88 __ __ __ __ - __ __- __ __

Specify other assessment:89

Was intervention given for relapsed, persistent or progressive disease, or decreased/loss of chimerism since the date of last report?

Yes No

90

Intervention Given (1) Questions: 91 - 103

Specify reason for which intervention was given91

Minimal residual disease

Persistent disease

Relapsed disase

Central nervous system irradiation

yes no

92

Intrathecal therapy

yes no

93

Systemic therapy

yes no

94

Date therapy was first started95

Known

Unknown

Previously reported (e.g. started in a prior reporting period/continued from prior reporting period)

Date first started:96 __ __ __ __ - __ __- __ __

Specify systemic therapy given (check all that apply)

Azacytidine

All-trans retinoic acid

Arsenic

Cladribine

Clofarabine

Cytarabine (Ara ­ C) ≤ 10 g/m2/cycle

cytarabine (Ara - C) > 10 g/m2/cycle

Daunorubicin

Decitabine

Etoposide

Fludarabine

Gemtuzumab

Idarubicin

Midostaurin

Mitoxantrone

Sorafenib

Thioguanine

Other systemic therapy

97

(Vidaza)

(Tretinoin)

(2-CDA, Leustatin)

(Cerubidine)

(Dacogen) 

(VP-16, VePesid)

(Fludara)

(Mylotarg)

(Idamycin)

(Novantrone)

(6-TG)

Specify other systemic therapy:98

Cellular therapy (e.g. donor cellular infusions (DCI), CAR T-cells)99

yes -Also complete Pre-CTED form 4000

no

Subsequent HCT100

yes -Also complete Pre-TED form 2400

no

Accelerated withdrawal of immunosuppression in response to disease assessment

Yes No

101

Other therapy

yes no

102

Specify other therapy:103

Disease Status at the Time of Evaluation for this Reporting Period Questions: 104 - 145

Does the disease status reflect the disease detected in this reporting period section without subsequent therapy? (as captured in questions 51-89)

Yes No Not Applicable

104

Were tests for molecular markers performed? (e.g. PCR, NGS)

yes no Unknown

105

CEBPA

Positive Negative Not Done

106

Specify CEBPA mutation107

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

108

FLT3 – ITD mutation

Positive Negative Not Done

109

IDH1

Positive Negative Not Done

110

IDH2

Positive Negative Not Done

111

KIT

Positive Negative Not Done

112

NPM1

Positive Negative Not Done

113

Current Molecular Marker (1) Questions: 114 - 115

Other molecular marker

Positive Negative Not Done

114

Specify other molecular marker:115

Was the disease status assessed via flow cytometry?

yes no

116

Blood

yes no

117

Date sample collected:118 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

119

Specify percent disease detected:120 %

Bone marrow

yes no

121

Date sample collected:122 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

123

Specify percent disease detected:124 %

Were cytogenetics tested? (karyotyping or FISH)

yes no Unknown

125

Were cytogenetics tested via FISH?

yes no Unknown

126

Results of tests127

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities128

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

129

Specify other abnormality:130

Were cytogenetics tested via karyotyping?

Yes No Unknown

131

Results of tests132

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities133

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

134

Specify other abnormality:135

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

136

Was the disease status assessed by clinical / hematologic assessment?

yes no

137

Date assessed:138 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

139

Was disease status assessed by other assessment?

Yes No

140

Date assessed:141 __ __ __ __ - __ __- __ __

Specify other assessment:142

Was disease detected?

yes no

143

What is the current disease status?144

Complete remission (CR)

Not in complete remission

Date assessed:145 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Specify molecular markers identified at time of best response:

Specify tissue and results at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify therapy given:

Specify systemic therapy given for reasons other than relapse or persistent disease:

Specify molecular markers identified since the date of last report:

Specify tissue and results:

Specify site(s) of disease:

Specify the method(s) used to assess the disease status at the time of evaluation for this reporting period:

Specify molecular markers identified:

Specify tissue and results at the time of evaluation for this reporting period:

Specify cytogenetic abnormalities identified:

Specify cytogenetic abnormalities identified:

Center: CRID: 

Form 2110 R4.0: Acute Myelogenous Leukemia (AML) Post-Infusion Data

CIBMTR Form 2110 revision 4.0 last updated Wednesday, August 16, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 10 / 11



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Visit

100 day 6 months 1 year 2 years > 2 years,

Specify:

Disease Assessment at the Time of Best Response to HCT or Cellular Therapy Questions: 1 - 40

What was the best response to HCT or cellular therapy since the date of the last report? (Include response to any therapy given for post-HCT / post-infusion maintenance or
consolidation, but exclude any therapy given for relapsed, persistent, or progressive disease)

1

Continued complete remission (CCR) - For patients transplant in CR

Complete
remission (CR)

- All of the following response criteria without progression for at least four weeks: < 5% blasts in the bone marrow, no blasts with Auer rods, no
extramedullary disease (e.g., central nervous system or soft tissue involvement)

Not in complete remission

Was the date of best response previously reported?

yes no

2

Date assessed:3 __ __ __ __ - __ __- __ __

Were tests for molecular markers performed? (e.g. PCR, NGS) (at time of best response)

yes no Unknown

4

CEBPA

Positive Negative Not Done

5

Specify CEBPA mutation6

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

7

FLT3 – ITD mutation

Positive Negative Not Done

8

IDH1

Positive Negative Not Done

9

IDH2

Positive Negative Not Done

10

KIT

Positive Negative Not Done

11

NPM1

Positive Negative Not Done

12

Multiple Molecular Markers (1) Questions: 13 - 14

Other molecular marker

Positive Negative Not Done

13

Specify other molecular marker:14

Was the disease status assessed via flow cytometry?

yes no

15

Blood

yes no

16

Date sample collected:17 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

18

Specify percent disease detected:19 %

Bone marrow

yes no

20

Date sample collected:21 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

22

Specify percent disease detected:23 %

Were cytogenetics tested (karyotyping or FISH)? (at time of best response)

yes no Unknown

24

Were cytogenetics tested via FISH?

Yes No

25

Results of tests26

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities27

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

28

Specify other abnormality:29

Were cytogenetics tested via karyotyping?

Yes No

30

Results of tests31

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities32

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

33

Specify other abnormality:34

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

35

Was disease status assessed by other assessment?

Yes No

36

Date assessed:37 __ __ __ __ - __ __- __ __

Specify other assessment:38

Was disease detected?

yes no

39

Was the status considered a disease relapse?

yes no

40

Post-HCT / Post-InfusionTherapy Questions: 41 - 50

Was therapy given since the date of the last report for reasons other than relapse or persistent disease? (Include any maintenance and consolidation therapy.)

yes no

41

Central nervous system irradiation

yes no

42

Systemic therapy

yes no

43

Date therapy was first started44

Known

Unknown

Previously reported (e.g. started in/continuing from a prior reporting period)

Date first started:45 __ __ __ __ - __ __- __ __

Specify systemic therapy given (for reasons other than relapse or persistent disease (check all that apply)

Azacytidine

All-trans retinoic acid

Decitabine

Intrathecal therapy

Midostaurin

Sorafenib

Thioguanine

Other systemic therapy

46

(Vidaza)

(Tretinoin)

(Dacogen)

(6-TG)

Specify other systemic therapy:47

Cellular therapy (e.g. donor cellular infusions (DCI),CAR T-cells)48

yes -Also complete Pre-CTED form 4000

no

Other therapy

yes no

49

Specify other therapy:50

Disease Detection Since the Date of Last Report Questions: 51 - 103

Were tests for molecular markers performed? (and positive for disease) (e.g. PCR, NGS)

yes no Unknown

51

Date sample collected:52 __ __ __ __ - __ __- __ __

CEBPA

Positive Negative Not Done

53

Specify CEBPA mutation54

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

55

FLT3 – ITD mutation

Positive Negative Not Done

56

IDH1

Positive Negative Not Done

57

IDH2

Positive Negative Not Done

58

KIT

Positive Negative Not Done

59

NPM1

Positive Negative Not Done

60

Multiple Molecular Markers (1) Questions: 61 - 62

Other molecular marker

Positive Negative Not Done

61

Specify other molecular marker:62

Was disease detected via flow cytometry?

Yes No

63

Blood

yes no

64

Date sample collected:65 __ __ __ __ - __ __- __ __

Specify percent disease detected:66 %

Bone marrow

yes no

67

Date sample collected:68 __ __ __ __ - __ __- __ __

Specify percent disease detected:69 %

Was disease detected via cytogenetics testing? (karyotyping or FISH)

Yes No Unknown

70

Were cytogenetic abnormalities identified via FISH?

Yes No

71

Date sample collected:72 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

73

Specify other abnormality:74

Were cytogenetic abnormalities identified via karyotyping?

Yes No

75

Date sample collected:76 __ __ __ __ - __ __- __ __

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

77

Specify other abnormality:78

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

79

Was disease detected by clinical / hematologic assessment?

Yes No

80

Date assessed:81 __ __ __ __ - __ __- __ __

Central nervous system

Yes No

82

Skin

yes no

83

Soft tissue

yes no

84

Other site

yes no

85

Specify other site:86

Was disease detected by other assessment?

Yes No

87

Date assessed:88 __ __ __ __ - __ __- __ __

Specify other assessment:89

Was intervention given for relapsed, persistent or progressive disease, or decreased/loss of chimerism since the date of last report?

Yes No

90

Intervention Given (1) Questions: 91 - 103

Specify reason for which intervention was given91

Minimal residual disease

Persistent disease

Relapsed disase

Central nervous system irradiation

yes no

92

Intrathecal therapy

yes no

93

Systemic therapy

yes no

94

Date therapy was first started95

Known

Unknown

Previously reported (e.g. started in a prior reporting period/continued from prior reporting period)

Date first started:96 __ __ __ __ - __ __- __ __

Specify systemic therapy given (check all that apply)

Azacytidine

All-trans retinoic acid

Arsenic

Cladribine

Clofarabine

Cytarabine (Ara ­ C) ≤ 10 g/m2/cycle

cytarabine (Ara - C) > 10 g/m2/cycle

Daunorubicin

Decitabine

Etoposide

Fludarabine

Gemtuzumab

Idarubicin

Midostaurin

Mitoxantrone

Sorafenib

Thioguanine

Other systemic therapy

97

(Vidaza)

(Tretinoin)

(2-CDA, Leustatin)

(Cerubidine)

(Dacogen) 

(VP-16, VePesid)

(Fludara)

(Mylotarg)

(Idamycin)

(Novantrone)

(6-TG)

Specify other systemic therapy:98

Cellular therapy (e.g. donor cellular infusions (DCI), CAR T-cells)99

yes -Also complete Pre-CTED form 4000

no

Subsequent HCT100

yes -Also complete Pre-TED form 2400

no

Accelerated withdrawal of immunosuppression in response to disease assessment

Yes No

101

Other therapy

yes no

102

Specify other therapy:103

Disease Status at the Time of Evaluation for this Reporting Period Questions: 104 - 145

Does the disease status reflect the disease detected in this reporting period section without subsequent therapy? (as captured in questions 51-89)

Yes No Not Applicable

104

Were tests for molecular markers performed? (e.g. PCR, NGS)

yes no Unknown

105

CEBPA

Positive Negative Not Done

106

Specify CEBPA mutation107

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

108

FLT3 – ITD mutation

Positive Negative Not Done

109

IDH1

Positive Negative Not Done

110

IDH2

Positive Negative Not Done

111

KIT

Positive Negative Not Done

112

NPM1

Positive Negative Not Done

113

Current Molecular Marker (1) Questions: 114 - 115

Other molecular marker

Positive Negative Not Done

114

Specify other molecular marker:115

Was the disease status assessed via flow cytometry?

yes no

116

Blood

yes no

117

Date sample collected:118 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

119

Specify percent disease detected:120 %

Bone marrow

yes no

121

Date sample collected:122 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

123

Specify percent disease detected:124 %

Were cytogenetics tested? (karyotyping or FISH)

yes no Unknown

125

Were cytogenetics tested via FISH?

yes no Unknown

126

Results of tests127

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities128

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

129

Specify other abnormality:130

Were cytogenetics tested via karyotyping?

Yes No Unknown

131

Results of tests132

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities133

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

134

Specify other abnormality:135

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

136

Was the disease status assessed by clinical / hematologic assessment?

yes no

137

Date assessed:138 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

139

Was disease status assessed by other assessment?

Yes No

140

Date assessed:141 __ __ __ __ - __ __- __ __

Specify other assessment:142

Was disease detected?

yes no

143

What is the current disease status?144

Complete remission (CR)

Not in complete remission

Date assessed:145 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Specify molecular markers identified at time of best response:

Specify tissue and results at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify cytogenetic abnormalities identified at time of best response:

Specify therapy given:

Specify systemic therapy given for reasons other than relapse or persistent disease:

Specify molecular markers identified since the date of last report:

Specify tissue and results:

Specify site(s) of disease:

Specify the method(s) used to assess the disease status at the time of evaluation for this reporting period:

Specify molecular markers identified:

Specify tissue and results at the time of evaluation for this reporting period:

Specify cytogenetic abnormalities identified:

Specify cytogenetic abnormalities identified:

Center: CRID: 

Form 2110 R4.0: Acute Myelogenous Leukemia (AML) Post-Infusion Data

CIBMTR Form 2110 revision 4.0 last updated Wednesday, August 16, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 11 / 11